738 related articles for article (PubMed ID: 29482895)
1. Bispecific antibody based therapeutics: Strengths and challenges.
Thakur A; Huang M; Lum LG
Blood Rev; 2018 Jul; 32(4):339-347. PubMed ID: 29482895
[TBL] [Abstract][Full Text] [Related]
2. Bispecific Antibody (bsAb) Construct Formats and their Application in Cancer Therapy.
Acheampong DO
Protein Pept Lett; 2019; 26(7):479-493. PubMed ID: 30864494
[TBL] [Abstract][Full Text] [Related]
3. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials.
Hosseini SS; Khalili S; Baradaran B; Bidar N; Shahbazi MA; Mosafer J; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
Int J Biol Macromol; 2021 Jan; 167():1030-1047. PubMed ID: 33197478
[TBL] [Abstract][Full Text] [Related]
4. Bispecific Antibodies in the Treatment of Hematologic Malignancies.
Duell J; Lammers PE; Djuretic I; Chunyk AG; Alekar S; Jacobs I; Gill S
Clin Pharmacol Ther; 2019 Oct; 106(4):781-791. PubMed ID: 30770546
[TBL] [Abstract][Full Text] [Related]
5. Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
Wei J; Yang Y; Wang G; Liu M
Front Immunol; 2022; 13():1035276. PubMed ID: 36389699
[TBL] [Abstract][Full Text] [Related]
6. Recent advances of bispecific antibodies in solid tumors.
Yu S; Li A; Liu Q; Yuan X; Xu H; Jiao D; Pestell RG; Han X; Wu K
J Hematol Oncol; 2017 Sep; 10(1):155. PubMed ID: 28931402
[TBL] [Abstract][Full Text] [Related]
7. Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?
Demichelis-Gómez R; Pérez-Sámano D; Bourlon C
Curr Oncol Rep; 2019 Feb; 21(2):17. PubMed ID: 30715609
[TBL] [Abstract][Full Text] [Related]
8. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
Park JA; Cheung NV
J Hematol Oncol; 2020 Dec; 13(1):172. PubMed ID: 33303017
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in aggressive B-cell lymphomas.
Jacobson CA; Armand P
Best Pract Res Clin Haematol; 2018 Sep; 31(3):299-305. PubMed ID: 30213400
[TBL] [Abstract][Full Text] [Related]
10. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy.
Zhang T; Lin Y; Gao Q
Cancer Biol Med; 2023 Mar; 20(3):181-95. PubMed ID: 36971124
[TBL] [Abstract][Full Text] [Related]
11. Advances in the study of CD47-based bispecific antibody in cancer immunotherapy.
Zhang B; Li W; Fan D; Tian W; Zhou J; Ji Z; Song Y
Immunology; 2022 Sep; 167(1):15-27. PubMed ID: 35575882
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs.
Foster LH; Lum LG
Expert Opin Biol Ther; 2019 Jul; 19(7):707-720. PubMed ID: 31081696
[TBL] [Abstract][Full Text] [Related]
13. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges.
Suurs FV; Lub-de Hooge MN; de Vries EGE; de Groot DJA
Pharmacol Ther; 2019 Sep; 201():103-119. PubMed ID: 31028837
[TBL] [Abstract][Full Text] [Related]
14. Cancer Immunotherapy: The Dawn of Antibody Cocktails.
Marrocco I; Romaniello D; Yarden Y
Methods Mol Biol; 2019; 1904():11-51. PubMed ID: 30539465
[TBL] [Abstract][Full Text] [Related]
15. Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response.
Park JA; Wang L; Cheung NV
J Hematol Oncol; 2021 Sep; 14(1):142. PubMed ID: 34496935
[TBL] [Abstract][Full Text] [Related]
16. Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer.
Huan T; Guan B; Li H; Tu X; Zhang C; Tang B
Hum Vaccin Immunother; 2023 Aug; 19(2):2256904. PubMed ID: 37772505
[TBL] [Abstract][Full Text] [Related]
17. Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy.
Groeneveldt C; Kinderman P; van den Wollenberg DJM; van den Oever RL; Middelburg J; Mustafa DAM; Hoeben RC; van der Burg SH; van Hall T; van Montfoort N
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082167
[TBL] [Abstract][Full Text] [Related]
18. The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies.
Swan D; Routledge D; Harrison S
Br J Haematol; 2022 Feb; 196(3):488-506. PubMed ID: 34472091
[TBL] [Abstract][Full Text] [Related]
19. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics.
Li H; Er Saw P; Song E
Cell Mol Immunol; 2020 May; 17(5):451-461. PubMed ID: 32313210
[TBL] [Abstract][Full Text] [Related]
20. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.
Shim H
Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
